View source for Bacterial galactosidases Efficient biocatalysts pertaining to bioprocess technological innovation

6%), with renal complications and road traffic accidents accounting for 2.2% each. Patients' age ranged from 31 to 84 years, with a modal age of 57 years. There was a male predominance with a male-to-female ratio of 1.51. Systemic hypertension co-morbidity was statistically significantly more common in patients aged 60 and above (P = 0.035). The most common lesion observed in the kidneys was benign nephrosclerosis (43.2%). Conclusions This study suggests that majority of our patients with diabetes mellitus die from infections with attendant sepsis. Older patients appear to have co-morbid systemic hypertension. Patient education on infection prevention and prompt treatment might be life-saving.Hypertension or high blood pressure is the foremost risk factor of cardiovascular diseases which in turn are the leading cause of death globally. Despite the widespread use of antihypertensive medication, the condition remains a global health concern. In a bid to ascertain that other therapies such as psychological treatment may be adopted as complementary treatments for hypertension, this paper therefore examines literature on the effectiveness of behavioural therapy in the treatment of hypertension, identify the technique which seems most effective though blood pressure reductions, highlight other hypertension-related domains and report sustainability of blood pressure control post-intervention. A systematic literature review of randomised control trials reporting the effectiveness of behaviour therapy on blood pressure among hypertensive adults, published between the years 2014 and 2018, was conducted. A total of 79 articles were identified from the database search after which 11 met the inclusion criteria, with 10 of the 11 studies reporting behavioural therapy to be effective in blood pressure control. Relaxation therapy and meditation training appeared to be most effective as they brought about the most significant decrements in blood pressure. The mean blood pressure reduction ranged from 2.88-36.33 mmHg (systolic) to 0.04-21.48 mmHg (diastolic). [https://www.selleckchem.com/products/sgc707.html Epigenetics inhibitor] Blood pressure control was found to have been sustained from between 0.7 and 24 months post-intervention. From this current paper, behaviour intervention is a viable, albeit complementary treatment method for hypertension; however, there is the need for more research to be conducted in various parts of the world, specifically in Nigeria and in Africa at large to allow for more relatable report on this topic.Sample size is one of the important considerations at the planning phase of a research proposal, but researchers are often faced with challenges of estimating valid sample size. Many researchers frequently use inadequate sample size and this invariably introduces errors into the final findings. Many reviews on sample size estimation have focused more on specific study designs which often present technical equations and formula that are boring to statistically naïve health researchers. Therefore, this compendium reviews all the common sample size estimation formula in social science and health research with the aim of providing basic guidelines and principles to achieve valid sample size estimation. The simplification of the sample size formula and detailed explanation in this review will demystify the difficulties many students as well as some researchers have with statistical formulae for sample size estimation.Background/Aim The treatment efficacy of Helicobacter pylori (H. pylori) has been decreasing over time due to resistance to multiple antimicrobial therapies. The most effective treatment regimen for Saudi Arabian patients infected with H. pylori is still unknown. We aimed to study the eradication rate of 10 days of quadruple therapy; bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline 125 mg for H. pylori infection in a Saudi population. Patients and Methods This was a prospective, open-label, non-randomized controlled trial. Patients with H. pylori infection were diagnosed by upper gastrointestinal (GI) endoscopy and rapid urease test (RUT) or histology. Patients who tested positive were recruited. Eligible patients were prescribed a 10-day course of quadruple therapy and received three capsules 4 times daily for 10 days along with omeprazole 20 mg twice daily. H. pylori was considered eradicated if the urea breath test (UBT) was negative after 6 weeks of completing the treatment. Results Ninety-two patients with H. pylori infection were recruited. Three patients withdrew from the trial and another seven patients lost follow-up. We analyzed 82 patient's data as per-protocol analysis, of whom 66 (80%) were naive to H. pylori treatment. Four patients had failed previous treatment with the sequential regimen and 12 patients had treatment with clarithromycin-based triple therapy. The post-treatment UBT for H. pylori infection was negative by per-protocol analysis in 72/82 patients (87.8%), and 72/92 (78.3%) by intention-to-treat analysis. There was no correlation between previous treatment failure and treatment response to the bismuth-based quadruple therapy (P value = 0.28). Conclusions Treatment with a bismuth-based quadruple therapy was effective in eradicating H. pylori infection in 78.3% of Saudi patients with an ITT analysis and in 87.8% as per-protocol analysis.Background/Aim Treatment of Helicobacter pylori infections has become more difficult because of increasing antibiotic resistance. We assessed the efficacy and safety of treatment with probiotics followed by a tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for H. pylori infection. Patients and Methods This retrospective study examined patients with at least two H. pylori eradication failures. Patients were given a two-week compound Lactobacillus acidophilus (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy. Eradication was evaluated using the[13]C-urea breath test at 4 weeks after the end of therapy, and side effects were recorded. Results The records of 50 patients were examined. Four cases experienced treatment failure, and one case received replacement with metronidazole because of allergy to furazolidone.